The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of immune checkpoint inhibitors in patients with non–small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions.
 
Hai-Yan Tu
Honoraria - AstraZeneca; Lilly; Pfizer; Roche; Sanofi
 
Kai Yin
No Relationships to Disclose
 
E-E Ke
No Relationships to Disclose
 
Si-Pei Wu
No Relationships to Disclose
 
Xiaotian Zhao
Employment - Nanjing
 
Yang-Si Li
No Relationships to Disclose
 
Mei-Mei Zheng
No Relationships to Disclose
 
Si-Yang Maggie Liu
No Relationships to Disclose
 
Yue-Li Sun
No Relationships to Disclose
 
Jia-Xin Lin
No Relationships to Disclose
 
Xiao-Yan Bai
No Relationships to Disclose
 
Yi-Chen Zhang
No Relationships to Disclose
 
Qing Zhou
Honoraria - AstraZeneca; Lilly; Pfizer; Roche; Sanofi
 
Jin-Ji Yang
No Relationships to Disclose
 
Wenzhao Zhong
No Relationships to Disclose
 
Bin-Chao Wang
No Relationships to Disclose
 
Dongqin Zhu
No Relationships to Disclose
 
Lingling Yang
Employment - Nanjing
 
Qiuxiang Ou
Employment - Geneseeq Technology Inc.
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)